3 Things to Expect from Novavax in 2021

Novavax (NASDAQ: NVAX) shares gained more than 2,600% last year as the clinical-stage biotech became one of the front-runners in the race to develop a coronavirus vaccine -- and was awarded $1.6 billion from the U.S. government to support its efforts.

That was a genuinely amazing performance, and as 2021 begins, Novavax still has a lot on its agenda. Here are three things investors should be looking for from the company this year.

Image source: Getty Images.

Source Fool.com